Nephron Pharmaceuticals Corp. is partnering with Clemson University to create a robotic solution for syringe-filling automation to enhance sterile manufacturing in the pharmaceutical production process and keep up with growing hospital demands.
 
Clemson’s robotics research for syringe automation will support the Nephron 503B Outsourcing Facility, a cGMP manufacturer providing sterile, pre-filled medications to address persistent drug shortages in hospitals and medical facilities across America.
 
“We are excited about our new partnership with Clemson, and we cannot wait to get started,” said Lou Kennedy, chief executive officer, Nephron. “Working together with Clemson’s world-class researchers and engineers, we can ensure that the pharmaceutical manufacturing process remains safe, and we can deliver life-saving drugs to patients and hospitals across the country.”
 
“When the External Affairs’ Office of Corporate Partnerships and Strategic Initiatives approached us about this project we were excited to get involved,” said Sophie Wang, associate professor of mechanical engineering, Clemson. “Our work in robotics can have a tremendous impact on individuals across the country and we are looking forward to working on this because of its benefits for the many patients Nephron serves.”
 
“Industry needs are changing at a rapid rate and Clemson is equipped to support companies like Nephron. Together, we have created a mutually beneficial project to enhance their capabilities while providing the University’s students with unique, hands-on research experience,” said Angie Leidinger, vice president for External Affairs’ Office of Corporate Partnerships and Strategic Initiatives at Clemson University. “This partnership is a testament to the work happening at Clemson and we’re looking forward to this collaboration, which will advance their business and benefit South Carolinians.”